MN-ENTRUST
19.10.2020 13:02:08 CEST | Business Wire | Press release
Entrust , a leading provider of trusted identities, payments and data protection, today announced the Sigma® Instant Desktop Issuance solution, an innovative direct-to-card solution for instant physical and mobile ID issuance. Designed for both cloud and on-premise deployment, the Sigma solution sets the standard for simple, secure and smart instant ID solutions across enterprise, healthcare, government, higher education and financial institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005238/en/
Today’s enterprises face a myriad of security challenges: From transitioning to digital operations during the pandemic, to managing the global rise in cyber-attacks, they must maintain a safe and secure flow of data − including the data stored on physical credentials. Within these organizations, Identity and Access Management professionals require a printing solution that is not only easy to integrate into their operations, but one that evolves to meet the growing needs of their company while assuring the highest level of data security. Sigma systems deliver a seamless user experience across the issuance process for desktop and mobile printing needs. It eliminates the frustrations of printer set-up with a modular design and an out-of-the-box implementation that takes less than 30 minutes for users to begin issuing identities.
Equipped with cloud-based APIs, Sigma systems bring issuance to the cloud without additional hardware — enabling instant printing for both physical IDs, badges and payment cards. Sigma systems are trusted IoT devices that help ensure organizations and their data are safe with an intelligent network and building connectivity for ultimate enterprise protection. With capabilities like tactile impressions, holographic and luster panel printing, Sigma printers make it highly difficult for counterfeiters to alter or recreate cards. Additionally, features like an inline magnetic stripe and smart card encoding secure your cards during the card printing process.
“With our Sigma platform, we’re proud to deliver a best-in-class desktop credential issuance solution that’s designed to work completely and securely within a cloud environment, allowing financial, enterprise, government, higher education and healthcare organizations to meet high-volume issuance demands without sacrificing security or ease of use. The Sigma system is ready to meet the issuance needs of today, and equally important, will evolve to meet tomorrow’s security and technology challenges with unlimited printing applications,” said Tony Ball, Senior Vice President and General Manager of Instant Issuance at Entrust. “Entrust has been a pioneer in direct-to-card identity issuance technology for decades, and our Sigma system takes it to a whole new level.”
Sigma systems offer the most advanced security architecture that keeps data protected at each step of the issuance process:
- Encrypted connections: The connection and data sent between software and the printer are secure and encrypted. Sigma printers do not store customer data after successful printing is complete.
- Secure boot: This feature prevents Sigma systems from booting up malware or other compromises are detected.
- Trusted platform module (TPM): Organizations can store and manage user certificates and keys in the printer, allowing the printer to become a trusted internet of things (IoT) endpoint.
As large segments of the workforce continue operating remotely, Sigma systems are poised to meet the demands of a hybrid workforce with its physical and digital issuance platform. The Sigma system’s “Printer Dashboard” is available on mobile devices, allowing organizations to manage the printer from anywhere, without being tied to a desktop. Sigma systems also enable companies to pivot and move to a contactless ID Issuance experience, from online photo submission to validating the photo, printing the card, and ultimately delivering the card to the employee. Furthermore, the on-premises instant ID solution features a mobile enrollment functionality for added flexibility to issue IDs at various locations within a facility. Sigma systems use intelligent instant ID technology to streamline printing and eliminate manual workflows — bringing simplicity, security and flexibility to the issuance process.
“Whether your requirements demand an integrated, secure on-premises solution or a system that can grow with a distributed workforce via a secure cloud-hosted Identity Management offering, the Entrust Sigma solutions can meet your needs,” said Joe Franco, Director of Sales at Capture Technologies, an Entrust channel partner. “They are browser based and mobile ready and able to be deployed without the need for a heavy client to be installed. The certificate based integrated security features should put to rest any concerns about using the cloud for identity issuance or your printing solution being vulnerable to network attack.”
For more information about Sigma visit: https://www.entrust.com/c/meet-sigma .
About Entrust
Entrust keeps the world moving safely by enabling trusted identities, payments and data protection. Today more than ever, people demand seamless, secure experiences, whether they’re crossing borders, making a purchase, accessing e-government services or logging into corporate networks. Entrust offers an unmatched breadth of digital security and credential issuance solutions at the very heart of all these interactions. With more than 2,500 colleagues, a network of global partners, and customers in over 150 countries, it’s no wonder the world’s most entrusted organizations trust us. To learn more, visit www.entrust.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005238/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
